ReviewInternational journal of molecular sciences2014
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.
Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 2 syntheses or guidelines pooled it, 355 citations in OpenAlex.
- The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.Cardiovascular & hematological disorders drug targets · 2025Pooled it
- Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.Nutrients · 2019Pooled it
- Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.Clinical immunology (Orlando, Fla.) · 2015Trial
- Ramadan Fasting in Metabolic Dysfunction-Associated Steatotic Liver Disease: Linking the Gut-Mitophagy-Circadian Axis to Endothelial Dysfunction and Hepatic Outcomes.Journal of personalized medicine · 2026Review
- Evaluating the effect of γ-oryzanol on MASLD pathology using a medaka fish model.FEBS open bio · 2026Article
- Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation.Journal of translational medicine · 2026Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies.Cardiovascular diabetology · 2026Observational
- Indonesian stingless bee propolis extract attenuates hepatic inflammation following a chronic high-saturated fat diet.BMC complementary medicine and therapies · 2026Article
- Pharmacological Targeting of NRF2 Represents a Promising Therapeutic Approach for Pyroptosis-Related Non-Alcoholic Fatty Liver Disease.Current medicinal chemistry · 2026Review
- Association betweenFrontiers in nutrition · 2026Article
- The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis.Frontiers in medicine · 2026Review
- Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption?World journal of hepatology · 2025Review
- Hepatoprotective effects of silibinin and chlorogenic acid standardised extract to alleviate the fatty liver syndrome and improve blood indices in caged-laying hens after the peak of production.Veterinary and animal science · 2025Article
- Mechanisms Linking Obesity with Non-Alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Diseases (CVDs)-The Role of Oxidative Stress.Current issues in molecular biology · 2025Review
- Review
- Multiple Machine Learning Identifies Key Gene PHLDA1 Suppressing NAFLD Progression.Inflammation · 2025Article
- Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.Antioxidants (Basel, Switzerland) · 2025Review
- Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression.Current obesity reports · 2025Review
- Applicability of multiple quantitative ultrasound liver biomarkers in children and adolescents with severe obesity.BMC pediatrics · 2025Article
145 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis and inflammation and, in some patients, progressive fibrosis leading to cirrhosis. An understanding of the pathogenesis of NASH is still evolving but current evidence suggests multiple metabolic factors critically disrupt homeostasis and induce an inflammatory cascade and ensuing fibrosis. The mechanisms underlying these changes and the complex inter-cellular interactions that mediate fibrogenesis are yet to be fully elucidated. Lipotoxicity, in the setting of excess free fatty acids, obesity, and insulin resistance, appears to be the central driver of cellular injury via oxidative stress. Hepatocyte apoptosis and/or senescence contribute to activation of the inflammasome via a variety of intra- and inter-cellular signalling mechanisms leading to fibrosis. Current evidence suggests that periportal components, including the ductular reaction and expansion of the hepatic progenitor cell compartment, may be involved and that the Th17 response may mediate disease progression. This review aims to provide an overview of the pathogenesis of NASH and summarises the evidence pertaining to key mechanisms implicated in the transition from steatosis and inflammation to fibrosis. Currently there are limited treatments for NASH although an increasing understanding of its pathogenesis will likely improve the development and use of interventions in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.